Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Steenokkerzeel – page 36

1 955 clinical trials in Steenokkerzeel, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Steenokkerzeel at a glance
1 955
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 955 trials in Steenokkerzeel

Open in trial search

Study on the Effects of Pitolisant Hydrochloride for Patients with Prader-Willi Syndrome

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pitolisant hydrochloride
  • Sponsor:Harmony Biosciences LLC

Study on How Well Etavopivat Works for Adolescents and Adults with Sickle Cell Disease

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Etavopivat
  • Sponsor:Novo Nordisk A/S

Study on Pembrolizumab for Patients with Early Triple-Negative Breast Cancer Responding Well to Initial Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Unicancer

Study on [18F]FAPI-74 for Better Cancer Imaging in Patients with Esophagogastric and Pancreatic Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:[Al[18F]F]Fapi-74
  • Sponsor:UZ Leuven

Study on Revumenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study on Toripalimab and Tifcemalimab for Patients with Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tifcemalimab
  • Sponsor:Shanghai Junshi Biosciences Co. Ltd.

Study of Zilovertamab Vedotin and Drug Combination for Untreated Diffuse Large B-Cell Lymphoma Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing the Safety and Effectiveness of Mexiletine PR and Mexiletine IR for Adults with Non-Dystrophic Myotonias

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mexiletine
  • Sponsor:Lupin Atlantis Holdings S.A.

Study of Olverembatinib and Bosutinib for Patients with Chronic Phase Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Ascentage Pharma Group Inc.

Study on Oxytocin and Mindfulness Training for Reducing Stress in Adults with Psychological Distress

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Oxytocin
  • Sponsor:UZ Leuven

Study on Acoramidis for Preventing Transthyretin Amyloidosis in Young People with a Genetic Risk

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis Hydrochloride
  • Sponsor:Eidos Therapeutics Inc.
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Autologous Adipose-Derived Stem Cells
  • Sponsor:Novadip Biosciences

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Steenokkerzeel

What the registry says about research in the country

01 Multiple Sclerosis Research

Innovative clinical trials focusing on relapsing multiple sclerosis, evaluating the effectiveness of new therapeutic compounds compared to established treatments.

  • Treatment Comparison Studies
  • Relapse Reduction Research
  • Safety Assessment Protocols

These studies aim to advance treatment options for patients experiencing MS relapses.

02 Progressive MS Studies

Specialized research examining nonrelapsing secondary progressive multiple sclerosis, with emphasis on disability progression prevention.

  • Disease Progression Analysis
  • Novel Therapeutic Approaches
  • Long-term Disability Management

Current trials are exploring innovative treatments to slow disease advancement.

03 Remyelination Research

Groundbreaking studies investigating brain remyelination and neurodegeneration in progressive multiple sclerosis using established medications in new applications.

  • Walking Speed Assessment
  • Disease Progression Markers
  • Alternative Treatment Applications

Research focuses on long-term treatment outcomes over 96-week periods.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.